| albumin-bound paclitaxel / Generic mfg. |
nabPCESCC, NCT01258192: Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients |
|
|
| Completed | 2 | 35 | RoW | albumin-bound paclitaxel plus cisplatin, nab-paclitaxel | Zhejiang Cancer Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University | Esophageal Squamous Cell Carcinoma | 10/12 | 10/12 | | |
NCT01372202: CHFR Methylation Status Esophageal Cancer Study |
|
|
| Terminated | 2 | 31 | US | Paclitaxel, Abraxane, Taxol, Cisplatin, Platinol, Oxaliplatin, Eloxatin, 5-Fluorouracil, 5-FU, Adrucil, Carac, Efudex, Fluorouracil, Radiotherapy, IMRT, Esophagectomy, Resection | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Esophageal Cancer | 06/14 | 10/14 | | |
NCT02033538: Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus |
|
|
| Withdrawn | 2 | 0 | RoW | nanoparticle albumin-bound paclitaxel, nab-paclitaxel | Zhejiang University | Squamous Cell Carcinoma of Esophagus | 12/15 | 12/16 | | |
NCT02034968: Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma |
|
|
| Withdrawn | 2 | 0 | RoW | Nimotuzumab, Anti epidermal growth factor receptor antibody h-R3 | Zhejiang University | Stage IV Esophageal Squamous Cell Carcinoma | 01/16 | 01/17 | | |
NCT02041819: Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus |
|
|
| Withdrawn | 2 | 0 | RoW | Nimotuzumab, nimo | Zhejiang University | Squamous Cell Carcinoma of Esophagus | 01/16 | 01/17 | | |
ACTION, NCT02273713: The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma |
|
|
| Completed | 1/2 | 154 | Europe | Nab-paclitaxel, Abraxane | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celgene Corporation | Esophageal Cancer, Toxicity | 03/17 | 03/17 | | |
